Poor Science; Poorly Trained Scientists; Poor Policies: Major Deterrents to the War on Cancer
- Authors
-
-
Leslie C. Costello
School of Dentistry Department of Oncology and Diagnostic Sciences and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
-
- Keywords:
- Cancer, NIH policies, training of scientists, excessive molecular biology, holistic physiological/pathophysiological approach.
- Abstract
-
Although the availability of funding has been described as the major limitation on advances in cancer, the progress in the war on cancer has been deterred mainly by poor science, poorly trained scientists, and poor NIH policies. This is the result of NIH policies of its extreme focus on molecular biology (genomics, molecular genetics, molecular biology) identification of the molecular factors and pathways; which are required for the acceptability of treatment and preventive protocols. As such, this has influenced virtually all agencies that provide grants for medical research to adopt the NIH policies. This has impacted the funding of the research as well as the focus of the training of scientists. Directors of NCI Dr. Varmus (also Nobel Prize awardee) and Dr. Zerhouni had addressed this issue; and they rejected the necessity of molecular biology studies and information. NIH should return to the holistic physiological/pathophysiological approach to studies of cancer issues. This would provide the best approach for winning the war on cancer.
- Downloads
-
Download data is not yet available.
- References
-
Zerhouni E. The NIH roadmap. Science 2003; 332: 63-5. https://doi.org/10.1126/science.1091867
Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149(6): 76-82.
Costello LC. The effect of contemporary education and training of biomedical scientists on present and future medical research. Acad Med 2009; 84: 459-63. https://doi.org/10.1097/ACM.0b013e31819a7c6b
Perspective: Is NIH funding the "best science by the best scientists"? A critique of the NIH R01 research grant review policies. Acad Med 2010; 85(5): 775-9. https://doi.org/10.1097/ACM.0b013e3181d74256
National Institutes of Health. Enhancing Peer Review at NIH: Overview. Available at: http://enhancing-peer-review.nih.gov/index.html. Accessed January 18, 2010
Office of Extramural Research, National Institutes of Health. Encouraging Early Transition to Research Independence: Modifying the NIH New Investigator Policy to Identify Early Stage Investigators. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-121.html. Accessed January 18, 2010.
Bernard C. An Introduction to the Study of Experimental Medicine. New York, NY: The Macmillan Company 1927.
- Downloads
- Published
- 15-08-2018
- Issue
- Vol. 7 No. 3 (2018)
- Section
- Articles
How to Cite
Similar Articles
- A. Lyberopoulou, E.P. Efstathopoulos, M. Gazouli, Nanodiagnostic and Nanotherapeutic Molecular Platforms for Cancer Management , Journal of Cancer Research Updates: Vol. 4 No. 4 (2015)
- Dimple Sethi Chopra , Challenges in Development of Nanomedicine for Treatment of Cancer , Journal of Cancer Research Updates: Vol. 8 No. 1 (2019)
- Lin Gao, Qinhe Yang, Wenbin Zhou, Yong Dai, Jigang Wang, Li Fu, Pan Zhao, Jingy Huang, Malin Hong, Jinquan Xia, Chang Zou, RNA-Sequencing-Based lncRNA Biomarker Profiling on Triple Negative Breast Cancer , Journal of Cancer Research Updates: Vol. 10 (2021)
- Yujie Xie, Liwu Fu, The Role of Exosomes and its Cargos in Drug Resistance of Cancer , Journal of Cancer Research Updates: Vol. 4 No. 4 (2015)
- Abdulkareem Ahmed, Ahmed Nihad, Ghaeeb Sabreen, Youssef Shakuri Yasin, Jumaa Azal, Synergistic Antiproliferative Effect of Linagliptin-Metformin Combination on the Growth of Hela Cancer Cell Line , Journal of Cancer Research Updates: Vol. 14 (2025)
- Kamal Asadipour, Narendra Banerjee, Jazmine Cuffee, Karrington Perry, Shennel Brown, Anasua Banerjee, Erik Armstrong, Stephen Beebe, Hirendra Banerjee, Studying the Role of Novel Carbon Nano Tubes as a Therapeutic Agent to Treat Triple Negative Breast Cancer (TNBC) - an In Vitro and In Vivo Study , Journal of Cancer Research Updates: Vol. 13 (2024)
- Dhafer A. Alghezi, Rasha Aljawher, Hameed Naeem Mosa, Increased KI67 Immunostaining is Associated with Breast Cancer Aggressiveness , Journal of Cancer Research Updates: Vol. 14 (2025)
- Sung-Han Hsiao, Shi-Yu Luo, Ching-Ya Su, Wei-Cherng Tuo, Cheng-Ting Chiang, Yan-Qing Li, Yang-Hui Huang, Chung-Pu Wu, The Overexpression of ABCG2 Reduces the Efficacy of Volasertib (BI 6727) and GSK641364 in Human S1-M1-80 Colon Carcinoma Cells , Journal of Cancer Research Updates: Vol. 3 No. 2 (2014)
- Herve Kada Pabame, Armel Herve Nwabo Kamdje, Richard Tagne Simo, Franklin Danki Sillong, Study of the Prevalence and the Incidence of the Prostate Cancer in the North-Cameroon: Means and Costs of Management , Journal of Cancer Research Updates: Vol. 7 No. 2 (2018)
- Kenichi Suda, Simon Ito, Hiroshi Mizuuchi, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi, EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
You may also start an advanced similarity search for this article.